Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial
Authors:
Open Access
- 23 September 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 24 (10) , 1928-1939
Abstract
Aims: In AFFIRM‐AHF, intravenous ferric carboxymaltose (FCM) reduced heart failure (HF) hospitalisations and improved quality of life versus placebo in iron‐deficient patients stabilised after an acute HF episode. This analysis explored the effects of FCM versus placebo in patients with ischaemic and non‐ischaemic HF aetiology. Methods and results: We included 1082 patients from AFFIRM‐AHF: 590 with ischaemic HF (defined as investigator‐reported ischaemic HF aetiology and/or prior acute myocardial infarction and/or prior coronary revascularisation) and 492 with non‐ischaemic HF. The prevalences of male sex, comorbidities, and history of HF were higher in the ischaemic versus non‐ischaemic HF subgroup. Annualised event rates for the primary composite outcome of total HF hospitalisations and cardiovascular death with FCM versus placebo were 65.3 versus 100.6 per 100 patient‐years in the ischaemic HF subgroup (rate ratio [RR] 0.65, 95% confidence interval [CI] 0.47–0.89, p = 0.007) and 58.3 versus 52.5 in the non‐ischaemic HF subgroup (RR 1.11, 95% CI 0.75–1.66, p = 0.60) ( p interaction = 0.039). An interaction between HF aetiology and treatment effect was also observed for the secondary outcome of total HF hospitalisations ( p interaction = 0.038). A nominal increase in quality of life, assessed using the 12‐item Kansas City Cardiomyopathy Questionnaire, was observed with FCM versus placebo, within each subgroup. Conclusions: Heart failure hospitalisations and cardiovascular deaths occurred at a higher rate in patients with ishaemic versus those with non‐ischaemic HF and were reduced by FCM versus placebo only in ischaemic patients. Further studies are needed to assess the role of aetiology in FCM efficacy.Keywords
Funding Information
- Vifor Pharma
This publication has 28 references indexed in Scilit:
- Mortality in systolic heart failure revisited: Ischemic versus non-ischemic cardiomyopathyInternational Journal of Cardiology, 2016
- Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencyEuropean Heart Journal, 2014
- High Prevalence of Iron Deficiency in Patients with Acute Decompensated Heart FailureEuropean Journal of Heart Failure, 2014
- Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failureEuropean Heart Journal, 2014
- Iron Deficiency Status Irrespective of Anemia: A Predictor of Unfavorable Outcome in Chronic Heart Failure PatientsCardiology, 2014
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Iron deficiency: an ominous sign in patients with systolic chronic heart failureEuropean Heart Journal, 2010
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009
- Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection FractionCirculation, 2009
- Subgroup analysis and other (mis)uses of baseline data in clinical trialsThe Lancet, 2000